text: <unk>  (initially known as ABT-773) is a macrolide antibiotic undergoing research for the treatment of community acquired pneumonia (CAP) and for the prevention of post-exposure inhalational anthrax, and was given an "orphan drug" status for this indication.  Originally discovered and developed by Abbott, it was acquired by Advanced Life Sciences Inc. for further development.
  On April 10, 2008, Advanced Life Sciences announced that, based on a productive meeting with the U.S. Food and Drug Administration (FDA), it plans to submit a New Drug Application (NDA) in the third quarter of 2008 for<unk>  to treat mild-to-moderate community acquired pneumonia.
option_0: Cethromycin
option_1: Tulathromycin
option_2: Erythromycin 
option_3: Fluclorolone
option_4: Lomefloxacin hydrochloride
option_5: Ciprofloxacin 
option_6: Meropenem
option_7: Cefmetazole